Leticia Martin
Overview
Explore the profile of Leticia Martin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
135
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Riano I, Martin L, Varela M, Serrano T, Nunez O, Minguez B, et al.
Cancers (Basel)
. 2020 Jul;
12(7).
PMID: 32674461
Pravastatin has demonstrated anti-tumor activity in preclinical and clinical studies. This multicentric randomized double-blind placebo-controlled phase II study (NCT01418729) investigated the efficacy and safety of sorafenib + pravastatin combination on...
2.
Buti M, Manzano M, Morillas R, Garcia-Retortillo M, Martin L, Prieto M, et al.
PLoS One
. 2018 Jun;
13(6):e0199926.
PMID: 29940039
[This corrects the article DOI: 10.1371/journal.pone.0184550.].
3.
Buti M, Manzano M, Morillas R, Garcia-Retortillo M, Martin L, Prieto M, et al.
PLoS One
. 2017 Sep;
12(9):e0184550.
PMID: 28898281
Background: Hepatitis B virus (HBV) reactivation in patients with resolved HBV infection (HBsAg negative, antiHBc positive) is uncommon, but potentially fatal. The role of HBV prophylaxis in this setting is...
4.
Alvarez P, Fernandez McPhee C, Prieto L, Martin L, Obiang J, Avedillo P, et al.
PLoS One
. 2016 Nov;
11(10):e0165333.
PMID: 27798676
Objectives: This is the first study describing drug resistance mutations (DRM) and HIV-1 variants among infected pregnant women in Equatorial Guinea (GQ), a country with high (6.2%) and increasing HIV...
5.
Alvarez P, Prieto L, Martin L, Obiang J, Avedillo P, Vargas A, et al.
Pediatr Res
. 2016 Sep;
81(1-1):80-87.
PMID: 27653084
Background: Early infant diagnosis (EID) of HIV-1 is necessary to reduce HIV-related mortality. As maternal antibodies transferred across the placenta may persist up to 18 mo, commercial virological assays (CVAs)...
6.
Alvarez P, Martin L, Prieto L, Obiang J, Vargas A, Avedillo P, et al.
J Infect
. 2015 Jun;
71(3):368-76.
PMID: 26033694
Objectives: Viral load (VL) testing is used for early HIV diagnosis in infants (EID) and for detecting early therapeutic failure events, but can be affected by HIV genetic variability. Dried...
7.
Holguin A, Norman F, Martin L, Mateos M, Chacon J, Lopez-Velez R, et al.
Clin Vaccine Immunol
. 2013 Jun;
20(8):1197-202.
PMID: 23740927
Trypanosoma cruzi serological screening is recommended for people potentially exposed to this parasite in countries where Trypanosoma cruzi is endemic and those where it is not endemic. Blood samples on...
8.
de Mulder M, Yebra G, Navas A, Martin L, de Jose M, Navarro M, et al.
Pediatr Infect Dis J
. 2012 Jul;
31(11):e213-21.
PMID: 22785049
Background: Drug resistance mutations compromise antiretroviral treatment (ART) effectiveness in HIV-1-infected children. Trends in drug resistance prevalence have not been previously evaluated in HIV-infected children in Spain. Methods: HIV-1 variants,...
9.
Yebra G, de Mulder M, Martin L, Rodriguez C, Labarga P, Viciana I, et al.
J Clin Microbiol
. 2011 Dec;
50(2):407-13.
PMID: 22162552
HIV-1 group M is classified into 9 subtypes, as well as recombinants favored by coinfection and superinfection events with different variants. Although HIV-1 subtype B is predominant in Europe, intersubtype...
10.
de Mulder M, Yebra G, Martin L, Prieto L, Mellado M, Rojo P, et al.
J Antimicrob Chemother
. 2011 Aug;
66(10):2362-71.
PMID: 21810838
Background: Drug resistance mutations affect antiretroviral therapy (ART) effectiveness in HIV-1-infected children, compromising long-term therapy. HIV-1 variants and drug resistance mutations were identified in HIV-infected children from Madrid, Spain. Methods:...